Endometrial cancer and application of proteomics

Experimental Oncology

Volumn 33, Issue 3, 2011, Pages 174-177

  Attarha, S ^a   Mints, M ^a   Andersson, S ^a   Souchelnytskyi, S ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CD171 ANTIGEN; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; CYCLOPHILIN A; EPIDERMAL FATTY ACID BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID BINDING PROTEIN; K RAS PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CALCYPHOSINE; PROTEIN KINASE; PROTEIN P16; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; UVOMORULIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CARCINOGENESIS; DIFFERENTIAL IN GEL ELECTROPHORESIS; ENDOMETRIOID CARCINOMA; ENDOMETRIOID ENDOMETRIAL CARCINOMA; ENDOMETRIUM CANCER; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HYSTERECTOMY; LYMPHADENECTOMY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; NON ENDOMETRIOID ENDOMETRIAL CARCINOMA; OMENTECTOMY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEOMICS; SALPINGOOOPHORECTOMY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICROSATELLITE INSTABILITY; PROGNOSIS; PROTEINS; PROTEOMICS;

EID: 80053422882     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology 2007; 39: 72-87.
3. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16: 8-13.
4. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 2008; 108: 221-9. (Pubitemid 351179637)
5. Frederick PJ, Straughn JM, Jr. The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Control 2009; 16: 23-9.
6. Goudge C, Bernhard S, Cloven NG, et al. The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer. Gynecol Oncol 2004; 93: 536-9. (Pubitemid 38507631)
7. Masciullo V, Amadio G, Lo Russo D, et al. Controversies in the management of endometrial cancer. Obstetrics and Gynecology International Volume 2010, Article ID 638165, 7 pages.
8. Montejo M, Werner TL, Gaffney D. Current challenges in clinical management of endometrial cancer. Advanced Drug Delivery 2009; 883: 889-61.
9. Gehrig PA, Bae-Jump VL. Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 2010; 187: 194-6.
10. Meehan KL, Rainczuk A, Salamonsen LA, et al. Proteomics and the search for biomarkers of female reproductive diseases. Reproduction 2010; 505: 519-40.
11. Sharon D, Chen R, Snyder M. Systems biology approaches to disease marker discovery. Disease Markers 2010; 28: 209-24.
12. Yi Z, Jingting C, Yu Z. Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells. Int J Gynecol Cancer 2009; 19: 326-33.
13. Monge M, Colas E, Doll A, et al. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 2009; 1288: 97-30.
14. Lambropoulou M, Papadopoulos N, Tripsianis G, et al. Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. J Cancer Res Clin Oncol 2010; 136: 427-35.
15. Li Z, Zhao X, Bai S, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 2008; 7: 1810-23.
16. Li Z, Huang C, Bai S, et al. Prognostic evaluation of epidermal fatty acid binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J. Cancer 2008; 2377: 2377-83.
17. Li Z, Min W, Huang C, et al. Proteomics-based approach identified differentially expressed proteins with potential roles in endometrial carcinoma. Int J Gynecol Cancer 2010; 9: 15-20.
18. Maxwell GL, Hood BL, Day R, et al. Proteomic analysis of stage I endometrial cancer tissue Identification of proteins associated with oxidative processes and inflammation. Gynecologic Oncology 2011; 121: 586-94.
19. DeSouza LV, Grigull J, Ghanny S, et al. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 2007; 6: 1170-82. (Pubitemid 47099227)
20. Kuruma H, Egawa S, Oh-Ishi M, et al. Proteome analysis of prostate cancer. Prostate Cancer Prostatic Diseases 2005; 14: 21-8.